Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Rating of “Moderate Buy” from Analysts

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $37.3333.

NBTX has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. Leerink Partners raised their price objective on Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 4th. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Guggenheim raised their price objective on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Finally, UBS Group raised their price objective on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st.

Nanobiotix Stock Performance

Nanobiotix stock opened at $35.54 on Friday. The stock’s fifty day moving average price is $37.63 and its two-hundred day moving average price is $29.41. Nanobiotix has a one year low of $4.18 and a one year high of $57.14.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The business had revenue of $3.42 million during the quarter. As a group, equities research analysts forecast that Nanobiotix will post 0.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Nanobiotix

Large investors have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in shares of Nanobiotix in the 4th quarter valued at $390,000. Marshall Wace LLP acquired a new stake in shares of Nanobiotix in the 4th quarter valued at $220,000. Royal Bank of Canada boosted its holdings in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Optiver Holding B.V. acquired a new stake in shares of Nanobiotix in the 3rd quarter valued at $101,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.